Objective: The objective was to determine whether bisphenol-A (BPA) is found in maternal circulation of pregnant women in the US population and is related to gestational length and birth weight.
Introduction
Environmental endocrine disrupting chemicals are hormonally active compounds that interfere with the normal functioning of the endocrine system. 1 Exposure to environmental endocrine disrupting chemicals appears to be a significant and contentious public health issue. 2 In recent years, attention has focused on human exposure to bisphenol-A (BPA), a widely used industrial plasticizer. Every year, over six billion pounds of BPA are used in the manufacture of epoxy resins and polycarbonate plastics used in a wide variety of domestic products. 3 BPA accounts for most of estrogenic activity in landfill leachates. 4 BPA is used in the manufacture of epoxy resins and polycarbonate plastics that are used in dental fillings, plastic food and commercially available water containers, baby bottles and food wrap, as well as in the lining of beverage and food cans, thus presenting a large number of possibilities for human exposure. [5] [6] [7] [8] Small quantities of BPA have been detected in river water and sediments, [9] [10] [11] and more recently, in indoor air and dust. 12 There is long-standing evidence that BPA can bind to the estrogen receptor and induce estrogen receptor-mediated gene expression [13] [14] [15] although recent evidence suggests that BPA can also bind to the thyroid receptor and affect thyroid hormone signaling. 16 BPA does not bind to plasma estrogen-binding proteins that normally limit the bioavailability of estradiol. 17 Accumulation of BPA appears to occur in pregnant adult female subjects, 3 more likely in fat and other tissues. 7, 18, 19 BPA is particularly potent during fetal and neonatal development as the liver has limited capacity to deactivate BPA in fetuses and newborns, especially in humans. 17 It is becoming increasingly evident that inappropriate exposure to sex steroids/steroid mimics has an impact on fetal growth and organ differentiation. 20, 21 For instance, fetal exposure to excess prenatal testosterone, an estrogen precursor, from days 30 to 90 of gestation (term 147 days), resulted in intrauterine growth restriction (IUGR) and low birth weight offspring in sheep. [22] [23] [24] On the contrary, prenatal treatment with dihydrotestosterone, a nonaromatizable androgen, did not reduce birth weight (Padmanabhan V, unpublished) . Combined with the fact that in utero exposure to diethylstilbestrol (DES), an estrogenic agent, is associated with IUGR 25 and prenatal BPA treatment leads to low birth weight offspring in sheep, 26 these findings support the hypothesis that increased estrogen signaling during inopportune times of fetal development can lead to IUGR. As BPA can bind estrogen receptors, 13, 15 continued exposure to this compound during gestation is likely to have an impact on the developmental trajectory of the fetus.
The widespread presence of BPA and increased susceptibility of the developing fetus to estrogen mimics necessitates comprehensive evaluation of exposure levels in pregnant women. Studies from industrialized nations such as Germany and Japan, suggest that measurable levels of BPA are found in maternal circulation. [27] [28] [29] Similar studies have not been undertaken with pregnant women in the United States. The only available information in the US population relates to urinary levels of BPA metabolites in the general population. 30, 31 A recent CDC survey found higher BPA metabolites (inactive) in the urine of 6 to 9-year-old girls with body mass index (BMI) <85th percentile compared to those with BMI >85th percentile. 32 Urinary measures provide an index as to whether humans are exposed to BPA but do not indicate circulating levels. Assuming environmental exposure levels are similar, high levels of urinary metabolites would imply lower circulating levels of parent compound and vice versa. Considering the susceptibility of fetuses to endocrine-disrupting chemicals, it is important to gain an understanding of maternal circulating levels of BPA in the United States. Therefore, the objective of this study was to determine if BPA is found in the circulation of pregnant women in the US population.
Methods

Maternal sample collection
The study involved the use of maternal blood samples collected at the time of delivery from 40 pregnant mothers as part of standard clinical hospital procedures. Blood samples were collected beginning 4 August 2006 and continued until 2 November 2006 from pregnant women delivering at the University of Michigan Hospital in Ann Arbor, MI, USA. Maternal blood samples were drawn by venipuncture directly into a vacutainer tube, which contained EDTA. After procuring blood samples from the hospital, samples were placed in a cooler and transported to the research laboratory. Maternal blood samples were centrifuged at 3000 r.p.m. and plasma was transferred to a glass tube and placed in À80 1C freezer until time for BPA measurement. Human blood samples were handled according to the guidelines for safe laboratory practices. Identical collection and processing protocol were followed for all subjects. Information on first visitFweight, height, weight at time of delivery, gestational length and birth weightFwere obtained for each subject. Confidentiality was maintained by substituting a subject identification number in place of name and patient identification and thereby eliminating any link to the patient. All materials collected from a given subject and computer data were identified with this number. The Institutional Review Board of the University of Michigan reviewed and approved the research protocol.
As BPA is present in plastics and can leach into the blood, validations were also carried out to determine the degree of BPA contamination resulting from contact with plastics during collection. These include (1) comparison of BPA levels in plasma samples transferred with glass pipettes and plastic transfer pipettes and (2) recovery of BPA from blood, plasma and serum. These validations were carried out using sheep blood.
Transfer with glass or Pasteur pipettes
To determine whether transferring plasma with plastic transfer pipettes resulted in leaching of BPA into the sample, 10 ml blood samples were collected by venipuncture from three female sheep and transferred to EDTA tubes containing 112 ml of a stock solution of BPA (stock concentration: 0.45 mg ml À1 ; Aldrich #239658, 99 þ % pure; Sigma-Aldrich, St Louis, MO, USA) in absolute ethanol (Aaper Alcohol and Chemical Co, Shelbyville, KY, USA) to yield a final concentration of 5 ng ml À1 . Syringes and needles used for procurement of blood samples were from Becton Dickinson (Franklin Lakes, NJ, USA). The blood was then split in half using glass pipettes and samples were spun down. The resulting plasma was aspirated using either a glass (Fisher #13-678-7C flint glass pipettes; Fisher Scientific, Pittsburgh, PA, USA) or polyethylene plastic (Fisher #12-711-7 polyethylene) pipette into glass tubes and stored until BPA measurement.
Recovery of BPA from whole blood, plasma or serum Blood samples were collected from female sheep by venipuncture into glass tubes to which 5, 10 and 20 ng ml À1 BPA was added. Five milliliters from each BPA-spiked sample were then transferred to; (1) a heparinized glass tube and spun down for plasma; (2) a glass tube with no additives, allowed to clot for 2 h at room temperature and then spun down to recover serum and (3) a glass tube with no additives added, left as whole blood. Blood, plasma and serum samples were frozen and stored at À20 1C. The initial BPA spiking process took less than a minute to avoid complications from clotting. Recovery of BPA from whole blood, serum and plasma was then compared.
BPA measurements BPA levels in samples were quantified using a high-performance liquid chromatography (HPLC) coupled with API 2000 electrospray triple-quadruple mass spectrometer (ESI-MS/MS). Briefly, a 0.8 to 1 ml aliquot of blood was transferred into a 15 ml polypropylene tube and 10 ml of 1-ppm butylphenol was added as an internal standard. Samples were extracted twice with 5 ml of ethyl ether by shaking in an orbital shaker for 30 min. The ethyl ether (2 Â 5 ml) was pooled and evaporated to dryness under a gentle stream of nitrogen. The sample extract was then reconstituted with 0.5 ml of methanol. Standards of BPA were prepared in methanol at concentrations ranging from 0.2 to 100 ng ml À1 for calibration. Analyte separation and detection were carried out using an Agilent 1100 series HPLC interfaced with an Applied Biosystems API 2000 electrospray MS/MS (Applied Biosystems, Foster City, CA, USA). A 10 ml of the extract was injected onto an analytical column (Betasil C18, 100 Â 2.1 mm column; Thermo Electron Corporation, Waltham, MA, USA), which was connected to a Javelin guard column (Betasil C18, 20 Â 2.1 mm). The mobile phase comprised methanol and water at a gradient starting from 25% to 99% methanol in 4 min and held for 10 min before it was reversed to initial condition. The flow rate and the column temperature were 300 ml per min and 25 1C, respectively. The MS/MS was operated in the electrospray negative ion mode. Instrumental parameters were optimized to transmit the (M-H) negative ion before fragmentation to one or more product ions. For BPA, cone voltage and collision energies were 30 and 25 V, respectively. Capillary voltage was 4.5 KV and desolvation temperature was 400 1C. Data were acquired using multiple reaction monitoring (MRM) for the transitions of 227>212.
Quality assurance and quality control parameters include validation of the method by spiking BPA into blood matrices and passing through the entire analytical procedure to calculate recoveries of BPA through the analytical method. A procedural blank, containing milli-Q water in place of plasma, was analyzed with every set of 10 samples to check for interferences or laboratory contamination. The limit of detection was 0.5 ng ml À1 and this was calculated as twice that of the valid 'lowest acceptable calibration standard'. A curve point was deemed valid if (1) it was back-calculated to be within 30% of the theoretical value when evaluated versus the 1/x weighted curve and (2) the peak area of the standard was at least two times greater than the surrogate matrix blank. Trace levels of BPA present in blanks (<0.1 ng) were subtracted from sample values for determining the concentrations in samples. Reported concentrations were not corrected for the recoveries of butylphenol, the internal standard. Quantification was based on an external calibration curve prepared by injecting 10 ml of 0.2, 0.5, 1, 5, 10, 50 and 100 ng ml À1 standards.
Statistical analyses
Recovery of BPA with a glass and a plastic pipette and BPA from blood, serum, and plasma was compared using paired T-tests. Regression analyses were performed between maternal BPA measures and body weight gain, gestational length and birth weight.
Results Figure 1 shows the elution profile of BPA following HPLC separation of standards and samples. Detection limit of BPA was 0.5 ng ml À1 . Recovery of BPA from sheep samples transferred with plastic transfer and glass pipette averaged 85.9 ± 5.3 and 83.4±3.7%, respectively, and did not differ statistically. Recovery of BPA from sheep whole blood, serum and plasma was 72.8 ± 3.9, 88.8±9.8 and 83.1±12.8%, respectively. While there were no statistical differences, recovery from whole blood tended to be numerically lower. Table 1 summarizes details of the human study population and the range of BPA concentration of maternal circulation at the time Figure 3 summarizes the mean gestational length and the weight of offspring relative to maternal circulating levels of BPA (p5 or >5 ng ml
À1
). There were no differences in gestational length or birth weight of offspring relative to maternal BPA levels. Regression analyses also revealed no association between circulating BPA levels with any of the variables studied.
Discussion
This is the first study to document measurable levels of BPA in maternal blood of the US population. The soft extraction procedure used in this study suggests that levels measured in plasma are free from BPA rather than from conjugated BPA metabolites. Furthermore, sample collection, storage and analytical conditions used in this study do not support hydrolysis of any conjugated forms of BPA in blood. The highest circulating levels found in pregnant women from southeast Michigan are half as much as those achieved during early gestation in our recent sheep study 26 that resulted in low birth weight offspring and adult reproductive deficits, raising public concern over human fetal exposure to synthetic exogenous steroids.
The scientific dogma is that BPA cannot be a biologically important pollutant since the body metabolizes and excretes it relatively quickly. Dekant et al. 33 found that ingested BPA was metabolized completely to BPA monoglucuronide and was excreted into urine within 24 h in humans. Biotransformation studies carried out in rodent models indicate that BPA is extensively metabolized to biologically inactive glucuronide (57 to 98%) and up to 4% form sulfate conjugates, which are excreted through urine and feces leaving 1 to 12% active (unconjugated) BPA. 14, 34, 35 Our findings, similar to studies conducted in Germany and Japan, [27] [28] [29] provide evidence supporting the existence of significant levels of unconjugated BPA in the circulation of pregnant women in southeastern Michigan. Maternal levels found in our study in the United States are comparable to those reported in studies from other industrialized countries. [27] [28] [29] For instance, BPA levels in maternal circulation of German women ranged between 0.3 and 18.9 ng ml À1 (median 3.1 ng ml
À1
).
28
Before determining the biological significance of the levels of BPA found in maternal circulation, it was important to address how accurate these measures are. Considering that all the samples were acquired from one site and processed similarly by the same individuals, the range of maternal BPA concentrations achieved (below detection to >20 ng ml À1 ) suggest that leaching of BPA during handling, was likely to be at levels below the detection limit (0.5 ng ml À1 ). Recovery studies carried out with sheep blood also provide further evidence that leaching of BPA from plastic syringe during sampling and transfer was minimal. BPA levels in HPLC blanks were also below the detection limit. While it is conceivable that low levels of BPA may have leached into the sample, this contribution is likely to be less than 0.5 ng ml À1 (detection limit) as the background from blanks were consistently low and subtracted from concentrations measured in samples. Taken together, these findings suggest that the levels of BPA measured in circulation of pregnant women living in southeastern Michigan are relatively accurate.
How are the levels of BPA seen in maternal blood related to fetal exposure levels and well-being? Although we did not measure BPA in fetal circulation, other studies suggest that the fetus is likely to be exposed to similar (if not higher) levels of BPA as the mother. Evidence exists in support of the passage of BPA across the placenta, 28 (high levels of BPA were also reported in human amniotic fluid 28, 30 ) and in umbilical cord blood. 27, 28 As most biotransformation enzymes such as uradinediphosphateglucuronosyltransferase are not produced until after birth 36 and the rate of BPA clearance from the fetal circulation is slower than from maternal circulation, 37 any toxic effects of BPA are likely to be amplified in the fetus. Animal studies have provided evidence that fetal exposure to low levels of BPA can influence development, growth and reproduction. 3, [38] [39] [40] [41] To what extent do these studies relate to any threat posed in humans is a contentious topic. 3, 42, 43 We recently found reduced birth weight and adult reproductive deficits in sheep following sustained maternal exposure to BPA 26 (at twice the levels found in human maternal circulation [27] [28] [29] (also this study)).
Lack of association between maternal levels of BPA at term and gestational length/birth weight in this study fails to address whether BPA, at levels found in human maternal circulation, poses risks to fetal well-being. A first limitation of this study is that measures of BPA were obtained at birth and not early/mid gestation, a time when organ differentiation occurs and the fetus is vulnerable to insults. Other studies have found differences in amniotic fluid levels of BPA with higher levels found in samples obtained during early than late pregnancy. 27 Second, conventional birth weight standards appear not to be sufficient for assessing fetal growth restriction in preterm infants. 44 As a result, offspring weight range seemingly appropriate for gestational age may have abnormal body composition and thus not provide an index of risk. Third, postnatal consequences for the offspring born to these women are yet to be determined. Fourth, the sample size of 40 is small and the role of potentially confounding variables such as economic status and race were not considered in this study and may be an important variable. Fifth, the BPA levels reported here represent the freely available form in blood; glucuronide conjugates were not measured in this study. A prospective study with a larger cohort that relates BPA levels across gestation with various fetal measures and postnatal developmental measures is needed to truly address this question.
Our study also found no association between BMI at first prenatal visit and BPA assessment at birth. As mentioned previously, a recent CDC survey found higher BPA metabolites (inactive) in 6 to 9-year-old girls with BMI <85th percentile compared to those with BMI >85th percentile. 32 Assuming that environmental exposure levels are similar between these BMI groups, this would imply the reverse in circulation, namely high levels of parent (active) BPA levels in girls with BMI>85th percentile. In the absence of assessment of BPA levels at the first prenatal visit, the findings from this study cannot address the impact of obesity on circulating BPA levels.
Could racial disparities in exposure to BPA contribute to welldocumented disparities in pregnancy outcome between African Americans and whites 45 in the United States? Minority communities are disproportionately exposed to environmental pollutants through residential segregation and other social structural factors. [46] [47] [48] BPA accounts for most estrogenic activity that leaches from landfills into the surrounding ecosystem, neighborhoods where African Americans predominate. 4 African-American communities also have fewer sources of fresh food and a higher proportion of fast food restaurants. This could potentially contribute to greater exposure to BPA. 49, 50 This is a question that warrants further investigation. In conclusion, our findings document the presence of BPA in maternal circulation in samples from southeastern Michigan at levels close to what is shown to be detrimental to reproductive, metabolic and behavioral health in animal models. 3,38 -41 Longterm follow-up studies are required to determine whether BPA at levels found in human maternal circulation have an impact on the developmental trajectory of the offspring.
